SCHEMBL5859682

SCHEMBL5859682

COc1ccc(C(c2ccccc2)(c2ccc(OC)cc2)C(OC(=O)c2ccccc2)[C@H]2O[C@@H](n3ccc(N)nc3=O)C[C@@H]2O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.41
ST6GAL1 P15907 2/20 0.37
POLG P54098 2/20 0.36
MAPT P10636 3/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
P2RY2 P41231 3/20 0.35
P2RY4 P51582 3/20 0.35
P2RY6 Q15077 2/20 0.35
CACNA1F O60840 2/20 0.35
LMNA P02545 2/20 0.35
ALB P02768 2/20 0.35
CACNA1D Q01668 2/20 0.35
CACNA1S Q13698 2/20 0.35
CACNA1C Q13936 2/20 0.35
PDE3A Q14432 2/20 0.35
KDM4E B2RXH2 1/20 0.33
ABL1 P00519 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL887176 0.88 POLB (0.42) POLBST6GAL1POLGMAPTP2RY2
SCHEMBL5200171 0.86 POLB (0.40) POLBST6GAL1POLGMAPTP2RY2
SCHEMBL5318031 0.85 ST6GAL1 (0.45) ST6GAL1LMNA
SCHEMBL28516266 0.84 POLB (0.38) POLBST6GAL1POLGMAPTP2RY2
SCHEMBL8626101 0.83 POLB (0.40) POLBST6GAL1POLGMAPTP2RY2
SCHEMBL5859661 0.81 P2RX3 (0.43) POLB
SCHEMBL10430326 0.81 ST6GAL1 (0.41) POLBST6GAL1MAPTMEN1NPC1
SCHEMBL19642755 0.80 POLB (0.42) POLBST6GAL1POLGMAPTP2RY2
SCHEMBL16401937 0.80 POLB (0.39) POLBST6GAL1POLGMAPTP2RY2
SCHEMBL8491773 0.79 POLB (0.45) POLBST6GAL1POLGMAPTP2RY2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135564-B1 Reusable solid support for oligonucleotide synthesis UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) 2006-11-14 US disclosed
EP-0877751-B1 LINKER ARM FOR SOLID SUPPORT OLIGONUCLEOTIDE SYNTHESIS AND PROCESS FOR PRODUCTION THEREOF UNIV TECHNOLOGIES INT (CA) 2003-10-15 EP disclosed
US-20030129593-A1 Process for producing multiple oligonucleotides on a solid support UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. 2003-07-10 US disclosed
EP-0876390-B1 REUSABLE SOLID SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS, PROCESS FOR PRODUCTION THEREOF AND PROCESS FOR USE THEREOF UNIV TECHNOLOGIES INT (CA) 2002-06-12 EP disclosed
EP-0877751-A1 LINKER ARM FOR SOLID SUPPORT OLIGONUCLEOTIDE SYNTHESIS AND PROCESS FOR PRODUCTION THEREOF UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) 1998-11-18 EP disclosed
EP-0876390-A1 REUSABLE SOLID SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS, PROCESS FOR PRODUCTION THEREOF AND PROCESS FOR USE THEREOF UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) 1998-11-11 EP disclosed
WO-1997023496-A1 REUSABLE SOLID SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS, PROCESS FOR PRODUCTION THEREOF AND PROCESS FOR USE THEREOF UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) 1997-07-03 WO disclosed
WO-1997023497-A1 LINKER ARM FOR SOLID SUPPORT OLIGONUCLEOTIDE SYNTHESIS AND PROCESS FOR PRODUCTION THEREOF UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030129593-A1 Process for producing multiple oligonucleotides on a solid support RNGTT, IGF2BP1, IGF2BP2 POLB 104/4885ST6GAL1 3403/4885POLG 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.